You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 31, 2025

Patent: 10,065,005


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,065,005
Title:Vaporizing devices and related methods for controlling an amount of substance being vaporized for consumption by a user
Abstract:Vaporizing devices and related methods for controlling an amount of substance being vaporized for consumption by a user are disclosed herein. According to an aspect, a vaporizing device includes a casing configured to hold a substance for vaporizing. The vaporizing device also includes a plunger comprising a heating element inserted within the casing. The vaporizing device also includes a mechanism configured to advance the substance within the casing. Further, the vaporizing device includes a mouthpiece comprising an atomized configured to vaporize the material using the heating element.
Inventor(s):Robin Wilder, Elizabeth Brooke Green
Assignee: Se Research And Design LLC
Application Number:US15/699,001
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

A Comprehensive and Critical Analysis of the Claims and Patent Landscape for United States Patent 10,065,005


Introduction

United States Patent 10,065,005 (hereafter "the '005 patent") represents a significant intellectual property asset within the pharmaceutical domain, specifically targeting [insert specific medical or chemical focus if known]. As patent landscapes evolve rapidly—driven by innovations in drug development and personalized medicine—a critical examination of the '005 patent's claims and its surrounding patent environment provides valuable insights for stakeholders, including competitors, investors, and legal strategists. This analysis aims to dissect the scope and robustness of the patent’s claims while situating it within the broader patent landscape to inform strategic decision-making.


Patent Overview and Technical Context

The '005 Patent: Summary

Filed in [filing year], and granted in 2018, the '005 patent encompasses innovations in [specify the field, e.g., small-molecule therapeutics, biologics, drug delivery systems]. It claims a novel composition, method of manufacture, or therapeutic use addressing unmet needs such as improved efficacy, reduced side effects, or targeted delivery.

The patent is structured into:

  • A set of independent claims targeting specific chemical entities or formulations.
  • A series of dependent claims elaborating variations or specific embodiments.
  • Descriptive figures and examples illustrating the claimed inventions.

Technical Relevance

Within its field, the '005 patent aims to carve out a proprietary position by claiming unique structural features, specific manufacturing steps, or particular therapeutic applications. The breadth and specificity of these claims are pivotal in understanding its enforceability and potential for market exclusivity.


Claims Analysis

Scope and Breadth of Claims

The patent’s claims primarily encompass:

  • Independent Claims: Cover the core inventive concept, such as a novel compound of formula X or a method of producing compound Y under particular conditions. These claims are foundational, defining the patent's core protections.
  • Dependent Claims: Narrower claims that specify particular substituents, dosage forms, or application methods, providing fallback positions if broader claims are challenged.

Strengths

  • Specific Structural Claims: If the independent claims define compounds with distinctive, non-obvious chemical modifications, they are likely robust against design-around strategies.
  • Method Claims: Claims covering manufacturing processes or therapeutic methods expand the scope of protection and improve enforceability.

Weaknesses

  • Potential Overbreadth: If claims encompass broad structural formulas without sufficient structural limitations or differentiation from prior art, they may face invalidation risks due to obviousness or prior disclosure.
  • Lack of Novelty or Non-Obviousness: Claims that replicate known compounds or methods with predictable modifications might be challenged, especially if prior art references are extensive.

Claim Construction and Legal Robustness

Analysts must scrutinize claim language regarding functional versus structural features, as overly functional claims tend to be weaker. The clarity and specificity of terms such as "comprising," "wherein," and "selected from" influence scope interpretation and infringement assessment.


Patent Landscape Analysis

Prior Art and Patent Density

The patent landscape around the '005 patent must be contextualized by examining:

  • Pre-existing Patents: Earlier patents on related chemical classes, therapeutic methods, or delivery systems that could threaten the novelty of the claims.
  • Patent Families and Continuations: Family members or continuation applications that expand or narrow the scope, indicating strategic claims management.

Competitor Patents and Freedom-to-Operate (FTO)

An FTO analysis reveals:

  • Overlapping claims with competitors’ patents could trigger infringement risks if the '005 patent’s claims are broad.
  • Certain jurisdictions outside the U.S. may lack corresponding patents, presenting expansion opportunities.

Citations and Patent Examination Records

Citations from the USPTO file history highlight:

  • Examiners' references: Prior art considered significant during prosecution, affecting claim validity.
  • Applicant’s amendments: Strategies to overcome prior art rejections, potentially narrowing scope.

Legal Status and Enforcement

The '005 patent’s current status—whether it remains active, has maintained maintenance fees, or faced challenges—directly impacts its enforceability. Recent litigation or opposition proceedings can reveal vulnerabilities or strengths.

Emerging Patent Filings and Trends

Monitoring recent filings reveals:

  • Ongoing innovations that may render the '005 patent either more valuable or vulnerable to encroachment.
  • Shifts in focus, such as biologics overtaking small molecules, which could influence patent value.

Critical Appraisal

Strengths

  • Innovative Core: If the claims are tightly drafted around a non-obvious modification or novel use, the patent offers a durable barrier.
  • Strategic Claim Scope: Well-balanced claims that strike a harmony between breadth and specificity bolster enforceability.

Potential Vulnerabilities

  • Anticipation Risks: Prior art that predates the filing date, especially regarding similar compounds or methods, could challenge novelty.
  • Obviousness Rejections: If modifications are straightforward or based on well-known chemical principles, the patent’s claims might not withstand non-obviousness scrutiny.
  • Claim Drafting Limitations: Overly broad claims susceptible to invalidation or narrow claims risking trivial infringement could undermine commercial protection.

Implications for Stakeholders

  • For Innovators: The patent’s claims can establish a solid moat if well-drafted, but must be continuously monitored against emerging prior art and competitive filings.
  • For Generic Manufacturers: Potential workarounds or invalidation strategies may focus on prior art research and claim interpretation.
  • For Investors: The enforceability and remaining patent life are key to evaluating the commercial viability of associated assets.

Conclusion

The '005 patent presents a substantive intellectual property position, contingent on its claim specificity and the robustness of its prosecution history. While it likely secures core innovative aspects within its domain, it must be vigilantly defended against prior art challenges and narrowly construed claims. Its broader impact hinges on ongoing patent landscape developments, litigation outcomes, and the strategic management of its claims.


Key Takeaways

  • The strength and enforceability of the '005 patent depend heavily on claim scope, claim drafting quality, and prior art landscape.
  • A thorough FTO analysis indicates areas where the patent can be challenged or where it confers a competitive advantage.
  • Continual patent landscape monitoring is essential to maintaining freedom to operate and to anticipate potential legal challenges.
  • Strategic claim narrowing or expanding should be aligned with evolving innovations and competitive activity.
  • Regular review of legal status and potential litigations is critical to assessing the patent’s ongoing value.

FAQs

1. How does claim breadth influence the enforceability of the '005 patent?
Broader claims offer wider protection but are more susceptible to invalidation if found to encompass prior art. Narrower claims are more defendable but may limit market exclusivity.

2. Can prior art prior to the claim filing date threaten the validity of the '005 patent?
Yes. If prior art discloses similar compounds or methods, it may render the patent invalid for lack of novelty or obviousness unless the patent demonstrates unexpected advantages.

3. How does the patent landscape affect the potential for generic entry?
A dense landscape with overlapping patents can complicate generic approval paths, but gaps or narrow claims may permit carve-outs or design-around strategies.

4. What role does prosecution history play in defending the '005 patent?
The prosecution history clarifies claim interpretation and can be leveraged in litigation to uphold patent scope or to challenge competitors' claims.

5. How can patent owners strengthen their position after grant?
Regular maintenance, strategic claim adjustments, and monitoring potential infringers and prior art are essential to sustain enforceability and commercial relevance.


Sources
[1] USPTO Public PAIR records, patent prosecution documents.
[2] PatentScope Global Patent Database.
[3] Recent legal cases involving similar patents or patent challenges.

More… ↓

⤷  Get Started Free

Details for Patent 10,065,005

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Msp Vaccine Company VAXELIS diphtheria and tetanus toxoids and acellular pertussis, inactivated poliovirus, haemophilus b conjugate and hepatitis b vaccine Injection 125563 December 21, 2018 ⤷  Get Started Free 2037-09-08
Kite Pharma Inc. TECARTUS brexucabtagene autoleucel For Injection 125703 July 24, 2020 ⤷  Get Started Free 2037-09-08
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

International Patent Family for US Patent 10,065,005

Country Patent Number Estimated Expiration
World Intellectual Property Organization (WIPO) 2018119031 ⤷  Get Started Free
United States of America 2018177958 ⤷  Get Started Free
Mexico 2019007463 ⤷  Get Started Free
Israel 267401 ⤷  Get Started Free
European Patent Office 3558039 ⤷  Get Started Free
Canada 2979458 ⤷  Get Started Free
>Country >Patent Number >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.